Medical Oncology

Uzm. Dr. Burcu Gülbağcı

Doctor and researcher Dr. İsmail Fehmi Cumalıoğlu Şehir Hastanesi Tekirdağ
NeoplasmsBreast NeoplasmsCarcinoma, Transitional CellCarcinoma, Non-Small-Cell LungLung NeoplasmsCOVID-19
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source
  • Neoplasms 3 publications
    Source: OpenAlex / PubMed MeSHView publications
  • Breast Neoplasms 3 publications
  • Carcinoma, Transitional Cell 2 publications
  • Carcinoma, Non-Small-Cell Lung 2 publications
  • Lung Neoplasms 2 publications
  • COVID-19 2 publications

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyMedical Oncologysaglik.gov.trFrom source
  • InstitutionDr. İsmail Fehmi Cumalıoğlu Şehir Hastanesisaglik.gov.trFrom source
  • Area of workNeoplasmsExtracted from 3 publications · Model version —From source
  • Publications36 publicationsOpenAlex, ORCID, Europe PMCFrom source
  • ORCID0000-0002-5720-8254ORCIDFrom source
  • Last synchronised5 November 2026 10:37https://tekirdagsehir.saglik.gov.tr/TR-584380/doktorlarimiz.html#burcu-gulbagcisaglik.gov.tr

Scientific work

Publications on Neoplasms

36 publications

  1. Prognostic factors in avelumab maintenance therapy for metastatic urothelial carcinoma

    Immunotherapy, 2026

    DOI 10.1080/1750743x.2026.2722548 PMID 42683510 Open-access full textSource: OpenAlex

  2. Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

    Cancers, 2026

    DOI 10.3390/cancers18030394 PMID 41681877 1 citation (Europe PMC) Open-access full textSource: ORCID

  3. Prognostic Significance of the CPS-EG Score in Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy

    Cancers, 2026

    DOI 10.3390/cancers18142302 PMID 42512369 Open-access full textSource: ORCID

  4. Short-Term Biceps Muscle Wasting Assessed by Serial Ultrasound as a Predictor of Survival Duration in Terminally Ill Cancer Patients: A Retrospective Cohort Study

    Medicina, 2026

    DOI 10.3390/medicina62020292 PMID 41752691 Open-access full textSource: ORCID

  5. AGGF-1 Expression as a Predictive Biomarker for Anti-VEGF Therapy in Metastatic Colorectal Cancer

    Eurasian Journal of Medical Investigation, 2026

    DOI 10.14744/ejmi.263054 Source: OpenAlex

  6. Relationship Between Netrin-1 Staining and Neoadjuvant Treatment Response in HER2-Positive Locally Advanced Breast Cancer

    Cancer management and research, 2026

    DOI 10.2147/cmar.s551516 PMID 41710041 Open-access full textSource: Europe PMC

  7. Beyond tumor burden: PET/CT-derived psoas muscle quality and survival outcomes in metastatic NSCLC patients treated with nivolumab.

    BMC cancer, 2026

    DOI 10.1186/s12885-026-16210-z PMID 42192342 Open-access full textSource: ORCID

  8. Investigating the FIB-4 index and PET/CT metabolic parameters for the differentiation status of hepatocellular carcinoma

    The Annals of Clinical and Analytical Medicine, 2026

    DOI 10.4328/acam.50067 Open-access full textSource: OpenAlex

  9. Global research trends and intellectual structure of immune checkpoint inhibitor–associated pneumonitis: a bibliometric analysis (2000–2025

    Journal of Medicine and Palliative Care, 2026

    DOI 10.47582/jompac.1900478 Open-access full textSource: OpenAlex

  10. Association between serum preptin levels and bone metastasis in newly diagnosed prostate cancer: a prospective exploratory study

    Journal of bone oncology, 2026

    DOI 10.1016/j.jbo.2026.100794 PMID 42656999 Open-access full textSource: OpenAlex

View all 36 publications